ROMIDEPSIN AND CARFILZOMIB IN RELAPSED / REFRACTORY PERIPHERAL T‐CELL LYMPHOMA WITH ASSESSMENT OF H23B AS A PREDICTIVE BIOMARKER – THE UK NCRI SEAMLESS PHASE 1/2 ROMICAR TRIAL

G. P. Collins, S. Booth, L. R. Cherrill, D. Slade, C. Morland, L. Hopkins, E. Nagy, K. Linton, C. P. Fox, D. Lewis, A. Davies, G. Turner, G. Rees, C. Yap, K. Cwynarski

Research output: Contribution to journalArticlepeer-review

Original languageEnglish
JournalHematological oncology
Volume39
Issue numberS2
DOIs
Publication statusPublished - Jun 2021

Research Beacons, Institutes and Platforms

  • Manchester Cancer Research Centre

Cite this